Augustine Chung, MD
Critical Care Medicine · Burbank, CANPI 1972820934
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $839 of the $1,095 with a category attached, or 76.6%. Boehringer Ingelheim accounts for 78.7% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $735, 8.0 times the $91 reported in 2019.
Across 12 payments — averaging $91.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$862
- United Therapeutics Corporation$142
- Genentech, Inc.$79
- Mylan Specialty L.p.$12
Across 100 payments — averaging $1085.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$80K
- GSK$21K
- Boehringer Ingelheim International GmbH$5K
- United Therapeutics Corporation$3K
What the payments were for
- Travel & lodging$23822%
- Food & beverage$83977%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 7 | $862 |
| United Therapeutics Corporation | 2 | $142 |
| Genentech, Inc. | 2 | $79 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$395
How this compares
$1,095 in reported general payments places this provider in the 65th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 164 | $2,168,580 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 103 | $75,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $67,893 |
| Breo ElliptaFluticasone/Vilanterol | 87 | $57,081 |
| EliquisApixaban | 30 | $25,705 |
| Arnuity ElliptaFluticasone Furoate | 49 | $17,729 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $11,965 |
| Mycophenolate Mofetil | 69 | $8,710 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,766 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,021 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 122 | $2,859 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $2,831 |
| Prednisone | 206 | $1,609 |
| Azathioprine | 26 | $952 |
| Ventolin HfaAlbuterol Sulfate | 14 | $782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Combivent Respimat | $862 | $2,180,545176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Burbank
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
- Bassam YaghmourOrange$376K
- Xuanha WhiteSan Diego$343K
- Ken YonedaSacramento$173K
- Praveen AkuthotaSan Diego$169K
- Ivan ChengSan Francisco$162K
- Brian ShermanOxnard$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.